natgillin/translations-raw huggingface dataset:
A method for the arrangement of an anti-noise barrier according to any of the previous claims, wherein said sheet piles are inserted on the ground sinking said second part until said plate reaches the ground in such a way that the first part (2') results emerging from the ground, so that the arrangement on the ground of the foundation of the post are realized in a single phase, and then the sound-absorbent panels are connected to the first part (2') via said connection means (4, 5). 
Postupak za izradu ograde protiv buke prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se stupovi navedenih talpi umeću u tlo potiskujući navedeni drugi dio dok navedena ploča ne dosegne površinu tla na način da prvi dio (2') strši iz tla, tako da se temelji stupova postavljaju u zemlju u jednom koraku, a zatim se ploče koje absorbiraju zvuk povezuju na prvi dio (2') preko navedenih sredstava za povezivanje (4, 5).
The method according to claim 10, wherein said plate (3) is preliminarily mounted on said sheet pile (2) by forming in said plate a slot of a shape coinciding with the section of the sheet pile and through which the plate is made to slide along the sheet pile until the pre-chosen position is reached, and then the plate is rigidly connected to the sheet pile. 
Postupak prema zahtjevu 10, naznačen time, da je navedena ploča (3) prethodno postavljena na navedenu talpu (2), pritom tvoreći na navedenoj ploči utor podudarnog oblika s talpom, kroz koji se ploča klizno umeće duž talpe do unaprijed odredenog položaja, a zatim se ploča čvrsto spaja na talpu.
The method according to claim 10, wherein said plate (3) is welded to said sheet pile. 
Postupak prema zahtjevu 10, naznačen time, da je ploča (3) zavarena na navedenu talpu.
A compound represented by the following structural formula: wherein at least 50 % by weight of the compound is crystalline. 
Spoj predstavljen slijedećom strukturnom formulom: [image] gdje je barem 50% po masi spoja kristalno.
The compound of claim 10, wherein the disease or condition which can be influenced by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase (HSD) 1 is a metabolic disorder. 
Spoj prema zahtjevu 10, naznačen time da je bolest ili stanje na koje se može utjecati inhibiranjem enzima 11β-hidroksisteroid dehidrogenaze (HSD) 1 metabolički poremećaj.
A method for producing crystalline form I of a compound represented by the following structural formula: wherein the crystalline form I is characterized by at least three x-ray powder diffraction peaks at 2Θ angles selected from 12.5°, 12.9°, 14.8°, 20.0°, 22.2° and 26.1°; or 12.5°, 14.8°, 22.2° and 26.1 °; 
Postupak proizvodnje kristalnog oblika I spoja predstavljenog slijedećom strukturnom formulom: [image] gdje je kristalni oblik I naznačen sa barem tri pika difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 12.5°, 12.9°, 14.8°, 20.0°, 22.2° i 26.1°; ili 12.5°, 14.8°, 22.2° i 26.1°;
dissolving a free base of the compound in ethanol at a temperature below 30°C; 
otapanje slobodne baze spoja u etanolu pri temperaturi ispod 30°C;
the method comprising dissolving the compound in ethyl acetate at a temperature above 40°C; and allowing crystalline form II to form by cooling the dissolved compound (e.g ., at a temperature below 15°C). 
koji postupak sadrži otapanje spoja u etil acetatu pri temperaturi iznad 40°; te dopuštanje da se stvori kristalni oblik II hlađenjem otopljenog spoja (npr., pri temperaturi ispod 15°C).
A method for producing crystalline form II of a compound represented by the following structural formula: wherein the crystalline form II is characterized by at least seven x-ray powder diffraction peaks at 2Θ angles selected from 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° and 26.5°; 
Postupak proizvodnje kristalnog oblika II spoja predstavljenog slijedećom strukturnom formulom: [image] gdje je kristalni oblik II naznačen sa barem sedam pikova difrakcije x-zraka na prahu pri 2Θ kutovima odabranim od 13.3°, 13.7°, 15.7°, 17.6°, 19.3°, 19.7°, 20.9°, 21.3°, 21.9°, 23.3°, 25.6° i 26.5°;
dissolving a free base of the compound in isopropanol at a temperature above 40°C; 
otapanje slobodne baze spoja u izopropanolu pri temperaturi iznad 40°;
protonating the free base with hydrochloric acid; and allowing crystalline form II to form by cooling the dissolved protonated free base (e.g., at a temperature below 15°C). 
protoniranje slobodne baze klorovodičnom kiselinom; te dopuštanje da se stvori kristalni oblik II hlađenjem otopljene protonirane slobodne baze (npr., pri temperaturi ispod 15°C).
A method of mixing ingredients comprising solid thermoplastic particulates and a viscous material in a first container without first melting the solid thermoplastic particulates, the method comprising feeding a predispersion comprising a substantially homogeneous mixture of the solid thermoplastic particulates and a major portion of the viscous material and feeding the remaining minor portion of the viscous material into a first container to give added ingredients in the first container; and mixing the added ingredients in the first container, wherein the solid thermoplastic particulates comprises a thermoplastic material and the major portion of the viscous material comprises a sufficient excess quantity of a reactant for the thermoplastic material. 
Postupak za miješanje sastojaka, naznačen time, da podrazumijeva krute termoplastične čestice i viskozni materijal u prvom spremniku, bez prethodnog taljenja krutih termoplastičnih čestica, pri čemu postupak obuhvaća dovođenje u pre-disperziju uglavnom homogene smjese čvrstih termoplastičnih čestica i većeg dijela viskoznog materijala i dodavanje preostalog manjeg dijela viskoznog materijala u prvi spremnik da se dobiju tvari dodane u prvi spremnik; i miješanje dodanih sastojaka u prvom spremniku, pri čemu krute termoplastične čestice sadrže termoplastični materijal i najveći dio viskoznog materijala sadrži dovoljnu količinu viška reagensa za termoplastični materijal.
The method as in claim 1, the method further comprising a step before the feeding step, the further step comprising mixing the solid thermoplastic particulates and the major portion of the viscous material to give the predispersion. 
Postupak prema zahtjevu 1, naznačen time, da nadalje sadrži korak prije koraka dodavanja, a dodatni korak uključuje miješanje čvrstih termoplastičnih čestica i glavninu viskoznog materijala, čime se dobije pre-disperzija.
The method as in any one of the preceding claims, wherein the feeding steps respectively consist essentially of feeding a batch of the predispersion and a batch of the remaining portion of the viscous material into the first container. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da se koraci dodavanja redom sastoje u biti od dodavanja šarže pre-disperzije i šarže preostalog dijela viskoznog materijala u prvi spremnik.
The method as in claim 1 or 2, wherein the feeding steps respectively comprise continuously feeding the predispersion and the remaining portion of the viscous material into the first container; and the method further comprises intermittently or continuously removing a reaction product thereof from the first container. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da koraci dodavanja redom sadrže kontinuirano dovođenje pre-disperziju i preostali dio viskoznog materijala u prvi spremnik; a navedeni postupak dodatno obuhvaća povremeno ili kontinuirano uklanjanje njegovog reakcijskog proizvoda iz prvog spremnika.
The method as in claim 9, the method further comprises transesterifying the recycled poly(ethylene terephthalate) and reacting the added ingredients terephthalic acid and monoethylene glycol at a temperature of from 250 degrees Celsius to 270 degrees Celsius in such a way so as to produce ethylene terephthalate oligomers in the first container. 
Postupak prema zahtjevu 9, naznačen time, da postupak nadalje obuhvaća transesterifikaciju recikliranog polietilen tereftalata i reakciju dodanih sastojaka tereftalne kiseline i monoetilen glikola na temperaturi od 250 do 270 stupnjeva Celzija na način da se dobiju oligomeri etilen tereftalata u prvom spremniku.
The method as in claim 11, the method employing an apparatus to prepare the predispersion and feed the predispersion into the first container, wherein the apparatus is effective for mixing a material and wherein the apparatus comprises the device and a mixing portion comprising a second container; wherein the second container has a downstream outlet defining an opening and is sealably connected to the device around and proximal to the upstream apertures of the device in such a way that the device restricts the opening of the downstream outlet of the second container to the openings of the upstream apertures of the device; and the apparatus functions in such a way that when the second container of the apparatus contains a material, the material can be discharged from the apparatus via the device without clogging the device. 
Postupak kao u zahtjevu 11, naznačen time, da koristi aparat za pre-disperziju i punjenje pre-disperzije u prvi spremnik, pri čemu je aparat učinkovit za miješanje materijala i pri čemu aparat podrazumijeva uređaj i dio za miješanje koji sadrži drugi spremnik; pri čemu drugi spremnik ima ispust nizvodno koji definira otvor i nepropusno je spojen oko i u blizini otvora uzvodno na uređaju na način da uređaj ograničava otvaranje ispusta nizvodno drugog spremnika prema otvorima uzvodno na uređaju; i aparat djeluje na takav način da se, kada drugi spremnik aparata sadrži materijal, materijal može biti ispušten iz aparata putem uređaja bez začepljenja uređaja.
A method of decoding a video, the method comprising: 
Postupak dekodiranja videa pri čemu postupak sadrži:
introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and 
uvođenju u stanicu domaćina, koja je imortalizirana stanica iz ljudske krvi najmanje jedna nukleinska kiselina koja kodira u najmanju ruku dio navedenog proteina; i
it has a galactosylation degree on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of the protein molecules in said protein molecule composition, that is increased compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from CHOdhfr- [ATCC No. 
stupanj galaktoziliranja na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli proteina kod molekula proteina u navedenom pripravku s molekulom proteina mu je povećan u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
it has an amount of G2 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of said protein molecules in said protein molecule composition which is at least 5% higher compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from CHOdhfr- [ATCC No. 
ima količinu G2 struktura na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli proteina kod navedenih molekula proteina u navedenom pripravku s molekulom proteina koja je najmanje 5% veća u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
it has an amount of G0 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of said protein molecules in said protein molecule composition which is at least 5% lower compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from CHOdhfr- [ATCC No. 
sadrži količinu fukoze na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli proteina kod navedenih molekula proteina u navedenom pripravku s molekulom proteina koja je najmanje 5% manja u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
it comprises at least one carbohydrate structure containing bisecting GlcNAc; and/or (viii) it has a sialylation pattern which is altered compared to the sialylation pattern of at least one protein molecule composition of the same protein molecule isolated from CHOdhfr- [ATCC No. 
sadrži najmanje jednu ugljikohidratnu strukturu koja sadrži račvani GlcNAc; i/ili (viii) ima primijenjeni uzorak sijaliliranja u usporedbi s uzorkom sijaliliranja za pripravak s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
Method according to claim 1 or 2, wherein said sialylation pattern is characterised by at least one of the following characteristics: 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni uzorak sijaliliranja ima najmanje jednu od sljedećih značajki:
it comprises alpha2-6 linked NeuNAc; and/or it has an increased sialylation degree with an amount of NeuNAc on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of the protein molecules in said protein molecule composition which is at least 15% higher compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from CHOdhfr- [ATCC No. 
– sadrži a-2,6 vezani NeuNAc; i/ili – ima povećani stupanj sijaliliranja količinom NeuNAc na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli proteina kod molekula proteina u navedenom pripravku s molekulom proteina koja je najmanje 15% veća u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
CRL-9096] when expressed therein, and/or it comprises at least 20% more charged N-glycosidically linked carbohydrate chains of the total carbohydrate units or of at least one particular carbohydrate chain at a particular glycosylation site of the protein molecule of the protein molecules in said protein molecule composition compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from CHOdhfr- [ATCC No. 
CRL-9096 (CHOdhfr-) kada se tamo eksprimira, i/ili – sadrži najmanje 20% više nabijenih N-glikozidno vezanih ugljikohidratnih lanaca u ukupnim ugljikohidratnim jedinicama ili u najmanje jednom određenom ugljikohidratnom lancu na određenom mjestu glikoziliranja u molekuli proteina kod molekula proteina u navedenom pripravku s molekulom proteina u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
it has an increased activity and/or increased yield in particular compared to at least one protein molecule composition of the same protein molecule when expressed in the cell line CHOdhfr- [ATCC No. 
– ima povišenu aktivnost i/ili povećani prinos, osobito u usporedbi s pripravkom s najmanje jednom molekulom proteina za istu molekulu proteina kada se eksprimira u staničnoj liniji ATCC No.
CRL-9096]; it has an improved homogeneity in particular compared to at least one protein molecule composition of the same protein molecule when expressed in the cell line CHOdhfr- [ATCC No. 
CRL-9096 (CHOdhfr-); – ima poboljšanu homogenost, osobito u usporedbi s pripravkom s najmanje jednom molekulom proteina za istu molekulu proteina kada se eksprimira u staničnoj liniji ATCC No.
it has an increased average or maximum yield which is at least 10% higher than the yield of at least one protein molecule composition from the same protein molecule when expressed in the cell line CHOdhfr- [ATCC No. 
– ima povećani prosječni ili maksimalan prinos, koji je najmanje 10% veći od prinosa pripravka s najmanje jednom molekulom proteina iz iste molekule proteina kada se eksprimira u staničnoj liniji ATCC No.
CRL-9096]; and/or it has an improved homogeneity, which is an improved glycosylation homogeneity compared to at least one protein molecule composition of the same protein molecule when expressed in the cell line CHOdhfr- [ATCC No. 
CRL-9096 (CHOdhfr-); i/ili – ima poboljšanu homogenost, koja je poboljšana homogenost glikoziliranja u usporedbi s pripravkom s najmanje jednom molekulom proteina za istu molekulu proteina kada se eksprimira u staničnoj liniji ATCC No.
it has an increased activity compared to at least one protein molecule composition of the same protein molecule when expressed in the cell line CHOdhfr- [ATCC No. 
– ima povišenu aktivnost u usporedbi s pripravkom s najmanje jednom molekulom proteina za istu molekulu proteina kada se eksprimira u staničnoj liniji ATCC No.
CRL-9096]; in case said protein molecule is an antibody molecule, it has an increased Fc-mediated cellular cytotoxicity which is at least 2 times higher than the Fc-mediated cellular cytotoxicity of at least one antibody molecule composition from the same antibody molecule when expressed in the cell line CHOdhfr-[ATCC No. 
– u slučaju kada je navedena molekula proteina molekula protutijela, ima povećanu staničnu citotoksičnost vezanu uz Fc, koja je najmanje 2 puta veća od stanične citotoksičnosti vezane uz Fc pripravka s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
CRL-9096] or compared to a sialylation deficient cell line such as NM-F9 and NM-D4; (b) it comprises no detectable NeuGc 
CRL-9096 (CHOdhfr-) ili u usporedbi sa sijalilacijski deficijantnom staničnom linijom, poput DSM ACC2606 (NM-F9) i DSM ACC2605 (NM-D4); ili
introducing in a host cell of human myeloid leukaemia origin at least one nucleic acid encoding an antibody molecule or at least one part thereof; and 
uvođenja u stanicu domaćina podrijetlom iz ljudske mijeloidne leukemije najmanje jedne nukleinske kiseline koja kodira u najmanju ruku dio navedenog protutijela; i
CRL-9096] when expressed therein, and/or it comprises at least 20% more charged N-glycosidically linked carbohydrate chains of the total carbohydrate units or of at least one particular carbohydrate chain at a particular glycosylation site of the protein molecule of the protein molecules in said protein molecule composition compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from CHOdhfr- [ATCC No. 
CRL-9096 (CHOdhfr-) kada se tamo eksprimira; – sadrži najmanje 20% više nabijenih N-glikozidno vezanih ugljikohidratnih lanaca u ukupnim ugljikohidratnim jedinicama ili u najmanje jednom određenom ugljikohidratnom lancu na određenom mjestu glikoziliranja u molekuli protutijela kod molekula protutijela u navedenom pripravku s molekulom protutijela u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
CRL-9096]; and/or in case said protein molecule is an antibody molecule, it has an increased Fc-mediated cellular cytotoxicity which is at least 2 times higher than the Fc-mediated cellular cytotoxicity of at least one antibody molecule composition from the same antibody molecule when expressed in the cell line CHOdhfr-[ATCC No. 
CRL-9096 (CHOdhfr-); i/ili – ima povećanu staničnu citotoksičnost vezanu uz Fc, koja je najmanje 2 puta veća od stanične citotoksičnosti vezane uz Fc pripravka s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
CRL-9096]; and/or in case said protein molecule is an antibody molecule, it has an increased antigen mediated or Fc-mediated binding which is at least 50% higher than the binding of at least one antibody molecule composition from the same antibody molecule when expressed in the cell line CHOdhfr- [ATCC No. 
CRL-9096 (CHOdhfr-); i/ili – ima povećano vezanje vezano uz antigen ili uz Fc, koje je najmanje 50% veće od vezanja pripravka s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
CRL-9096] when expressed therein; it has a higher galactosylation degree with at least a 5% higher amount of G2 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the antibody molecule of the antibody molecules in said antibody molecule composition than the same amount of antibody molecules of at least one antibody molecule composition of the same antibody molecule isolated from CHOdhfr- [ATCC No. 
Pripravak s molekulom protutijela u skladu s jednim od patentnih zahtjeva 19 do 33, naznačen time što navedeno protutijelo ima veći stupanj galaktoziliranja najmanje 5% većom količinom G2 struktura na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod molekula protutijela u navedenom pripravku s molekulom protutijela nego ista količina molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
a serum half life which is elongated by factor 2 compared to an antibody which carries no or a low degree of detectable sialylation; 
poluvijek u serumu koji je 2 puta dulji u usporedbi s protutijelom koje nije sijalilirano ili ima nizak stupanj opazivog sijaliliranje;
it has an increased Fc-mediated cellular cytotoxicity which is at least 2 times higher than the Fc-mediated cellular cytotoxicity of at least one antibody molecule composition from the same antibody molecule when expressed in the cell line CHOdhfr- [ATCC No. 
ima povećanu staničnu citotoksičnost vezanu uz Fc, koja je najmanje 2 puta veća od stanične citotoksičnosti vezane uz Fc pripravka s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
a prolonged serum half-life compared to an antibody molecule composition of the same antibody molecule isolated from NM-F) when expressed therein; and/or 
produljeni poluvijek u serumu u usporedbi s pripravkom s molekulom protutijela za istu molekulu protutijela izoliranu iz NM-F kada se tamo eksprimira; i/ili
an amount of G2 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the antibody molecule of said antibody molecules in said antibody molecule composition which is at least 50% higher compared to the same amount of antibody molecules in at least one antibody molecule composition of the same antibody molecule isolated from CHOdhfr- [ATCC No. 
količinu G2 struktura na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 50% veća u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.